




Instance: composition-en-9f200c2b1188de65461c6911d6f9550c
InstanceOf: CompositionUvEpi
Title: "Composition for silodyx Package Leaflet"
Description:  "Composition for silodyx Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/09/607/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9f200c2b1188de65461c6911d6f9550c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - silodyx"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Silodyx is and what it is used for </li>
<li>What you need to know before you take Silodyx </li>
<li>How to take Silodyx </li>
<li>Possible side effects </li>
<li>How to store Silodyx </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What silodyx is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What silodyx is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Silodyx is </p>
<p>Silodyx belongs to a group of medicines called alpha1A-adrenoreceptor blockers. 
Silodyx is selective for the receptors located in the prostate, bladder and urethra. By blocking these 
receptors, it causes smooth muscle in these tissues to relax. This makes it easier for you to pass water 
and relieves your symptoms. </p>
<p>What Silodyx is used for </p>
<p>Silodyx is used in adult men to treat the urinary symptoms associated with benign enlargement of the 
prostate (prostatic hyperplasia), such as: 
* difficulty in starting to pass water, 
* a feeling of not completely emptying the bladder, 
* a more frequent need to pass water, even at night. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take silodyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take silodyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Silodyx </p>
<p>if you are allergic to silodosin or any of the other ingredients of this medicine (listed in section 6). </p>
<p>Warnings and precautions  </p>
<p>Talk to your doctor or pharmacist before taking Silodyx </p>
<ul>
<li>
<p>If you are undergoing eye surgery because of cloudiness of the lens (cataract surgery), it is 
important that you immediately inform your eye specialist that you are using or have previously 
used Silodyx. This is because some patients treated with this kind of medicine experienced a 
loss of muscle tone in the iris (the coloured circular part of the eye) during such a surgery. The 
specialist can take appropriate precautions with respect to medicine and surgical techniques to 
be used. Ask your doctor whether or not you should postpone or temporarily stop taking 
Silodyx when undergoing cataract surgery. </p>
</li>
<li>
<p>If you have ever fainted or felt dizzy when suddenly standing up, please inform your doctor 
before taking Silodyx.<br />
Dizziness when standing up and occasionally fainting may occur when taking Silodyx, 
particularly when starting treatment or if you are taking other medicines that lower blood 
pressure. If this occurs, make sure you sit or lie down straight away until the symptoms have 
disappeared and inform your doctor as soon as possible (see also section  Driving and using 
machines ).  </p>
</li>
<li>
<p>If you have severe liver problems, you should not take Silodyx, as it was not tested in this 
condition. </p>
</li>
<li>
<p>If you have problems with your kidneys, please ask your doctor for advice.<br />
If you have moderate kidney problems, your doctor will start Silodyx with caution and possibly 
with a lower dose (see section 3  Dose ).<br />
If you have severe kidney problems, you should not take Silodyx. </p>
</li>
<li>
<p>Since a benign enlargement of the prostate and prostate cancer may present the same symptoms, 
your doctor will check you for prostate cancer before starting treatment with Silodyx. Silodyx 
does not treat prostate cancer. </p>
</li>
</ul>
<p>The treatment with Silodyx may lead to an abnormal ejaculation (decrease in the amount of semen 
released during sex) that may temporarily affect male fertility. This effect disappears after 
discontinuation of Silodyx. Please inform your doctor if you are planning to have children.  </p>
<p>Sodium 
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 
 sodium-free . </p>
<p>Children and adolescents </p>
<ul>
<li>Do not give this medicine to children and adolescents below 18 years since there is no relevant 
indication for this age group. </li>
</ul>
<p>Other medicines and Silodyx </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Tell your doctor in particular, if you take: 
* medicines which lower blood pressure (in particular, medicines called alpha1-blockers, such 
as prazosin or doxazosin) as there may be the potential risk that the effect of these medicines is 
increased whilst taking Silodyx. 
* antifungal medicines (such as ketoconazole or itraconazole), medicines used for HIV-AIDS 
(such as ritonavir) or medicines used after transplants to prevent organ rejection (such as 
cyclosporin) because these medicines can increase the blood concentration of Silodyx. 
* medicines used for treating problems in getting or keeping an erection (such as sildenafil or 
tadalafil), since the concomitant use with Silodyx might lead to a slight decrease in blood 
pressure.<br />
* medicines for epilepsy or rifampicin (a medicine to treat tubercolosis), since the effect of 
Silodyx may be reduced. </p>
<p>Pregnancy and breast-feeding </p>
<p>Silodyx is not intended for use by women. </p>
<p>Fertilty </p>
<p>Urorec may reduce the amount of sperm, and so could temporarily affect your ability to father a child. 
If you are planning to have a baby, ask your doctor or pharmacist for advice before taking this 
medicine. </p>
<p>Driving and using machines </p>
<p>Do not drive or operate machines if you feel faint, dizzy, drowsy or have blurred vision. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take silodyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take silodyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is one capsule of Silodyx 8 mg per day by oral administration.  </p>
<p>Take the capsule always with food, preferably at the same time every day. Do not break or chew the 
capsule, but swallow it whole, preferably with a glass of water. </p>
<p>Patients with kidney problems<br />
If you have moderate kidney problems, your doctor may prescribe a different dose. For this purpose 
Silodyx 4 mg hard capsules are available. </p>
<p>If you take more Silodyx than you should </p>
<p>If you have taken more than one capsule, inform your doctor as soon as possible. If you become dizzy 
or feel weak, tell your doctor straight away. </p>
<p>If you forget to take Silodyx </p>
<p>You may take your capsule later the same day if you have forgotten to take it earlier. If it is almost 
time for the next dose, skip the dose you missed. Do not take a double dose to make up for a forgotten 
capsule. </p>
<p>If you stop taking Silodyx </p>
<p>If you stop treatment, your symptoms may re-appear. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.  </p>
<p>Contact your doctor immediately if you notice any of the following allergic reactions: swelling of the 
face or throat, difficulty in breathing, feeling faint, itchy skin or hives since the consequences could 
become serious. </p>
<p>The most common side effect is a decrease in the amount of semen released during sex. This effect 
disappears after discontinuation of Silodyx. Please inform your doctor if you are planning to have 
children. </p>
<p>Dizziness, including dizziness when standing up, and occasionally fainting, may occur.<br />
If you do feel weak or dizzy, make sure you sit or lie down straight away until the symptoms have 
disappeared. If dizziness when standing up or fainting occurs, please inform your doctor as soon as 
possible. </p>
<p>Silodyx may cause complications during a cataract surgery (eye surgery because of cloudiness of the 
lens, see section  Warnings and precautions ).<br />
It is important that you immediately inform your eye specialist if you are using or have previously 
used Silodyx. </p>
<p>The possible side effects are listed below:  </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
* Abnormal ejaculation (less or no noticeable semen is released during sex, see section  Warnings 
and precautions ) </p>
<p>Common side effects (may affect up to 1 in 10 people) 
* Dizziness, including dizziness when standing up (see also above, in this section) 
* Runny or blocked nose 
* Diarrhoea </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
* Decreased sexual drive 
* Nausea 
* Dry mouth 
* Difficulties in getting or keeping an erection 
* Faster heart rate 
* Symptoms of allergic reaction affecting the skin like rash, itching, hives and rash caused by a 
medicine 
* Abnormal results of liver function tests 
* Low blood pressure </p>
<p>Rare side effects (may affect up to 1 in 1,000 people) 
* Fast or irregular heart beats (called palpitations) 
* Fainting/ Loss of consciousness </p>
<p>Very rare side effects (may affect up to 1 in 10,000 people) 
* Other allergic reactions with swelling of the face or throat </p>
<p>Not known (frequency cannot be estimated from the available data) 
* Floppy pupil during cataract surgery (see also above, in this section) </p>
<p>If you feel that your sexual life is affected, please tell your doctor.  </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store silodyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store silodyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month. </p>
<p>Do not store above 30  C.<br />
Store in the original package in order to protect from light and moisture. </p>
<p>Do not use this medicine if you notice that is damaged or shows signs of tampering. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Silodyx contains </p>
<p>Silodyx 8 mg 
The active substance is silodosin. Each capsule contains 8 mg of silodosin.  </p>
<p>The other ingredients are pregelatinised maize starch, mannitol (E421), magnesium stearate, sodium 
laurilsulfate, gelatin, titanium dioxide (E171).  </p>
<p>Silodyx 4 mg 
The active substance is silodosin. Each capsule contains 4 mg of silodosin.  </p>
<p>The other ingredients are pregelatinised maize starch, mannitol (E421), magnesium stearate, sodium 
laurilsulfate, gelatin, titanium dioxide (E171), yellow iron oxide (E172). </p>
<p>What Silodyx looks like and contents of the pack </p>
<p>Silodyx 8 mg are white, opaque, hard gelatin capsules, size 0 (approximately 21.7 x 7.6 mm). </p>
<p>Silodyx 4 mg are yellow, opaque, hard gelatin capsules, size 3 (approximately 15.9 x 5.8 mm). </p>
<p>Silodyx is available in packs containing 5, 10, 20, 30, 50, 90, 100 capsules and in multipacks 
comprising 2 cartons, each containing 100 capsules. Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder </p>
<p>Recordati Ireland Ltd. 
Raheens East 
Ringaskiddy Co. Cork 
Ireland </p>
<p>Manufacturer </p>
<p>Recordati Industria Chimica e Farmaceutica S.p.A. 
Via Matteo Civitali 1 
20148 Milan 
Italy </p>
<p>Laboratoires Bouchara-Recordati 
Parc M catronic 
03410 Saint Victor 
France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:  </p>
<p>Belgi /Belgique/Belgien 
Recordati bv 
T l/Tel: +32 2 461 01 Lietuva 
Recordati Ireland Ltd. 
Tel: + 353 21 4379<br />
Recordati Ireland Ltd. 
Te .: + 353 21 4379Luxembourg/Luxemburg 
Recordati bv 
T l/Tel: +32 2 461 01  esk  republika 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Magyarorsz g 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Danmark 
Recordati Ireland Ltd. 
Tlf: + 353 21 4379Malta 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Deutschland 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Nederland 
Recordati bv 
Tel: +32 2 461 01 Eesti 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Norge 
Recordati Ireland Ltd. 
Tlf: + 353 21 4379<br />
   . . 
 : + 30 210 8009 sterreich 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Espa a 
Almirall, S.A. 
Tel: +34 93 291 30 Polska 
Recordati Ireland Ltd. 
Tel: + 353 21 4379France 
ZAMBON France 
T l: + 33 (0)1 58 04 41 Portugal 
Tecnimede Sociedade 
T cnico-Medicinal, S.A 
Tel: +351 21 041 41 Hrvatska 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Rom nia 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Ireland 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Slovenija 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 sland 
Recordati Ireland Ltd. 
S mi: + 353 21 4379Slovensk  republika 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Italia 
Takeda Italia S.p.A. 
Tel: +39 06 502Suomi/Finland 
Recordati Ireland Ltd. 
Puh/Tel: + 353 21 4379<br />
Recordati Ireland Ltd. 
 : + 353 21 4379Sverige 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Latvija 
Recordati Ireland Ltd. 
Tel: + 353 21 4379United Kingdom (Northern Ireland) 
Recordati Ireland Ltd. 
Tel: + 353 21 4379This leaflet was last revised in {MM/YYYY}. </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-9f200c2b1188de65461c6911d6f9550c
InstanceOf: CompositionUvEpi
Title: "Composition for silodyx Package Leaflet"
Description:  "Composition for silodyx Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/09/607/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp9f200c2b1188de65461c6911d6f9550c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - silodyx"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. INDLÆGSSEDDEL"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. INDLÆGSSEDDEL"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Indlægsseddel: Information til brugeren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Indlægsseddel: Information til brugeren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "Oversigt over indlægssedlen"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Oversigt over indlægssedlen"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal De vide, før De begynder at tage Silodyx </li>
<li>Sådan skal De tage Silodyx </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. Virkning og anvendelse"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. Virkning og anvendelse"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Silodyxs virkning </p>
<p>Silodyx tilhører en gruppe af lægemidler, der kaldes alfa1A-adrenoreceptorblokkere. 
Silodyx påvirker nogle receptorer, som findes i blærehalskirtlen, blæren og urinrøret. Ved at blokere 
disse receptorer, får det den glatte muskulatur i disse væv til at slappe af. Dette gør det lettere for Dem 
at lade vandet, og det lindrer Deres symptomer. </p>
<p>Silodyxs anvendelse </p>
<p>Silodyx anvendes hos voksne mænd for at behandle urinsvejssymptomer forbundet med en godartet 
forstørrelse af blærehalskirtlen (prostatahyperplasi), såsom: </p>
<ul>
<li>
<p>besvær med at påbegynde vandladning, </p>
</li>
<li>
<p>en følelse af at blæren ikke tømmes fuldstændigt, </p>
</li>
<li>
<p>et hyppigere behov for at lade vandet, selv om natten. </p>
</li>
</ul> </div>"""   
          

             
* section[=].section[+]
  * title = "2. Det skal du vide, før du begynder at tage  silodyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. Det skal du vide, før du begynder at tage  silodyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Silodyx </p>
<p>hvis De er allergisk over for silodosin eller et af de øvrige indholdsstoffer i Silodyx (angivet i 
punkt 6). </p>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller apotekspersonalet, før De tager Silodyx. </p>
<ul>
<li>
<p>Hvis De skal gennemgå en øjenoperation på grund af uklarhed af linsen (operation for grå 
stær), er det vigtigt, at De straks informerer Deres øjenspecialist om, at De tager eller tidligere 
har taget Silodyx. Dette skyldes, at nogle patienter, som blev behandlet med denne form for 
medicin, har været udsat for, at muskelspændingen i iris (den farvede cirkulære del af øjet) blev 
nedsat under sådan en operation. Specialisten kan tage de nødvendige forholdsregler angående 
medicin og den kirurgiske teknik, der anvendes. Spørg Deres læge om De bør udskyde eller 
midlertidigt stoppe med at tage Silodyx, hvis De skal gennemgå en operation for grå stær. </p>
</li>
<li>
<p>Hvis De på noget tidspunkt er besvimet eller har følt Dem svimmel, når De pludseligt rejser 
Dem op, skal De informere lægen før De tager Silodyx. 
Hvis De oplever svimmelhed, når De rejser Dem op, og hvis De besvimer ind imellem, når De 
tager Silodyx, specielt når De begynder med behandlingen, eller hvis De tager andre 
lægemidler, der sænker blodtrykket. Hvis dette forekommer, skal De straks sætte eller lægge 
Dem ned, indtil symptomerne er forsvundet, og informere Deres læge snarest muligt (se også 
punkt “Trafik- og arbejdssikkerhed"). </p>
</li>
<li>
<p>Hvis De har alvorlige leverproblemer, bør De ikke tage Silodyx, da det ikke er undersøgt i 
forbindelse med alvorlig leversygdom. </p>
</li>
<li>
<p>Hvis De har problemer med Deres nyrer, skal De rådføre Dem med Deres læge. 
Hvis de har moderate nyreproblemer, vil Deres læge begynde behandlingen med Silodyx med 
forsigtighed og muligvis med en lavere dosis (se punkt 3 “Dosis"). 
Hvis De har alvorlige nyreproblemer, bør De ikke tage Silodyx. </p>
</li>
<li>
<p>Da en godartet forstørrelse af blærehalskirtlen og prostatakræft kan have de samme symptomer, 
vil Deres læge undersøge Dem for prostatakræft, før De begynder behandlingen med Silodyx. 
Silodyx kan ikke anvendes til at behandle prostatakræft. </p>
</li>
<li>
<p>Behandling med Silodyx kan føre til unormal ejakulation (reduktion i mængden af sæd, der 
frigives under samleje), hvilket midlertidigt kan påvirke den mandlige frugtbarhed. Denne 
virkning forsvinder, når behandlingen med Silodyx ophører. Fortæl det til Deres læge, hvis De 
planlægger at få børn. </p>
</li>
</ul>
<p>Natrium 
Denne medicin indeholder mindre end 1 mmol natrium (23 mg) pr. kapsel, dvs. den er i det væsentlige 
natriumfri. </p>
<p>Børn og unge </p>
<p>Giv ikke dette lægemiddel til børn og unge under 18 år, da der ikke er nogen relevant indikation for 
denne aldersgruppe. </p>
<p>Brug af anden medicin sammen med Silodyx </p>
<p>Fortæl altid lægen eller apotekspersonalet, hvis De tager anden medicin eller har gjort det for nylig.  </p>
<p>Fortæl det især til Deres læge, hvis De tager: </p>
<ul>
<li>
<p>medicin, der sænker blodtrykket (især medicin kaldet alfa1-blokkere, såsom prazosin eller 
doxazosin), da der kan være en risiko for at virkningen af sådanne former for medicin 
forstærkes, mens De tager Silodyx. </p>
</li>
<li>
<p>medicin mod svampeinfektion (såsom ketoconazol eller itraconazol), medicin der anvendes 
mod HIV-infektion/AIDS (såsom ritonavir) eller medicin der anvendes efter </p>
</li>
</ul>
<p>transplantationer for at forhindre organafstødning (såsom ciclosporin), da disse former for 
medicin kan forhøje koncentrationen af Silodyx i blodet. </p>
<ul>
<li>
<p>medicin til behandling af problemer med at få og opretholde en erektion (såsom sildenafil 
eller tadalafil), da samtidig anvendelse med Silodyx kan føre til et let blodtryksfald.  </p>
</li>
<li>
<p>medicin mod epilepsi eller rifampicin (medicin til behandling af tuberkulose), da virkningen 
af Silodyx kan være nedsat. </p>
</li>
</ul>
<p>Graviditet og amning </p>
<p>Silodyx er kun beregnet til brug hos mænd. </p>
<p>Frugtbarhed </p>
<p>Silodyx kan nedsætte mængden af sædceller og dermed midlertidigt påvirke Deres evne til at gøre en 
kvinde gravid. Hvis De planlægger at blive far til et barn, skal De spørge Deres læge eller 
apotekspersonalet til råds, før De tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Kør ikke bil og betjen ikke maskiner hvis De føler dem svag, svimmel, døsig eller har sløret syn. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. Sådan skal du tage silodyx"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. Sådan skal du tage silodyx"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er De i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den anbefalede dosis er en kapsel Silodyx 8 mg pr. dag givet oralt (gennem munden). </p>
<p>Kapslen bør altid tages sammen med mad, helst på samme tid hver dag. Kapslen må ikke deles eller 
tygges, men skal synkes hel, helst med et glas vand. </p>
<p>Patienter med nyreproblemer 
Hvis De har moderate nyreproblemer, kan Deres læge ordinere en anden dosis. Til dette formål findes 
Silodyx 4 mg hårde kapsler. </p>
<p>Hvis De har taget for meget Silodyx </p>
<p>Fortæl det til Deres læge så hurtigt som muligt, hvis De har taget flere end én kapsel. Hvis De bliver 
svimmel eller føler Dem svag, skal De straks fortælle det til Deres læge. </p>
<p>Hvis De har glemt at tage Silodyx </p>
<p>De kan tage Deres kapsel senere samme dag, hvis De har glemt at tage den tidligere på dagen. Hvis 
det næsten er tidspunktet for den næste dosis, skal De springe den glemte dosis over. De må ikke tage 
en dobbeltdosis som erstatning for den glemte kapsel. </p>
<p>Hvis De holder op med at tage Silodyx </p>
<p>Hvis De holder op med behandlingen, kan Deres symptomer komme igen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Bivirkninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Bivirkninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Kontakt straks Deres læge, hvis De bemærker nogle af de følgende allergiske reaktioner: hævelse af 
ansigt eller hals, vejrtrækningsbesvær, følelse af at skulle besvime, hudkløe eller nældefeber, da 
konsekvenserne heraf kan blive alvorlige. </p>
<p>Den hyppigste bivirkning er en reduktion i mængden af sæd, som frigøres under samleje. Denne 
virkning forsvinder, når behandlingen med Silodyx ophører. Fortæl det til Deres læge, hvis De 
planlægger at få børn. </p>
<p>Svimmelhed, herunder svimmelhed når De rejser Dem op, og besvimelse ind imellem kan 
forekomme. 
Hvis De føler Dem svag eller svimmel, skal De sørge for at sætte Dem eller lægge Dem ned med det 
samme, indtil symptomerne forsvinder. Hvis der forekommer svimmelhed, når De rejser Dem op, eller 
besvimelse, skal De informere Deres læge så snart som muligt. </p>
<p>Silodyx kan forårsage komplikationer under en operation for grå stær (øjenoperation på grund af en 
uklar linse, se punktet “Advarsler og forsigtighedsregler"). 
Det er vigtigt, at De straks informerer Deres øjenspecialist, hvis De tager eller tidligere har taget 
Silodyx. </p>
<p>Mulige bivirkninger er anført nedenfor: </p>
<p>Meget almindelige bivirkninger(kan forekomme hos flere end 1 ud af 10 personer) </p>
<ul>
<li>Unormal ejakulation (mindre eller ikke registrerbar mængde sæd frigøres under samleje, se 
punktet “Advarsler og forsigtighedsregler") </li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer) </p>
<ul>
<li>
<p>Svimmelhed, herunder svimmelhed når De rejser Dem op (se også ovenfor i dette punkt) </p>
</li>
<li>
<p>Løbende eller tilstoppet næse </p>
</li>
<li>
<p>Diarré </p>
</li>
</ul>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer) </p>
<ul>
<li>
<p>Nedsat sexlyst </p>
</li>
<li>
<p>Kvalme </p>
</li>
<li>
<p>Mundtørhed </p>
</li>
<li>
<p>Problemer med at få eller vedligeholde rejsning af penis </p>
</li>
<li>
<p>Hurtigere puls </p>
</li>
<li>
<p>Symptomer på allergisk reaktion, der påvirker huden, som udslæt, kløe, nældefeber og 
lægemiddelfremkaldt udslæt  </p>
</li>
<li>
<p>Unormale resultater fra leverfunktionsprøver </p>
</li>
<li>
<p>Lavt blodtryk </p>
</li>
</ul>
<p>Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 personer) </p>
<ul>
<li>
<p>Følelse af hurtige eller uregelmæssige hjerteslag (hjertebanken eller palpitationer) </p>
</li>
<li>
<p>Besvimelse/bevidstløshed </p>
</li>
</ul>
<p>Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 personer) </p>
<ul>
<li>Andre allergiske reaktioner med hævelse af ansigt eller hals </li>
</ul>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra forhåndenværende data) </p>
<ul>
<li>Slap pupil under operation for grå stær (se også ovenfor i dette punkt) </li>
</ul>
<p>Tal med lægen, hvis De føler, at Deres seksualliv er påvirket. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. Opbevaring"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. Opbevaring"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og blisteren efter Exp. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C. 
Opbevares i den originale yderpakning for at beskytte mod lys og fugt. </p>
<p>Brug ikke lægemidlet, hvis det er beskadiget, eller pakningen viser tegn på, at den har været åbnet. </p>
<p>Spørg på apoteket, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Pakningsstørrelser og yderligere oplysninger"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Pakningsstørrelser og yderligere oplysninger"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Silodyx indeholder </p>
<p>Silodyx 8 mg 
Aktivt stof: silodosin. Hver kapsel indeholder 8 mg silodosin. </p>
<p>Øvrige indholdsstoffer: pregelatineret majsstivelse, mannitol (E421), magnesiumstearat, 
natriumlaurilsulfat, gelatine, titandioxid (E171). </p>
<p>Silodyx 4 mg 
Aktivt stof: silodosin. Hver kapsel indeholder 4 mg silodosin.  </p>
<p>Øvrige indholdsstoffer: pregelatineret majsstivelse, mannitol (E421), magnesiumstearat, 
natriumlaurilsulfat, gelatine, titandioxid (E171), gul jernoxid (E172). </p>
<p>Udseende og pakningsstørrelser </p>
<p>Silodyx 8 mg er hvide, uigennemsigtige, hårde gelatinekapsler, størrelse 0 (cirka 21,7 x 7,6 mm). </p>
<p>Silodyx 4 mg er gule, uigennemsigtige, hårde gelatinekapsler, størrelse 3 (cirka 15,9 x 5,8 mm).. </p>
<p>Silodyx leveres i pakninger med 5, 10, 20, 30, 50, 90, 100 kapsler og i multipakninger bestående af 2 
kartoner med hver 100 kapsler. Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Recordati Ireland Ltd. 
Raheens East 
Ringaskiddy Co. Cork 
Irland </p>
<p>Fremstiller </p>
<p>Recordati Industria Chimica e Farmaceutica S.p.A. 
Via Matteo Civitali 1 
20148 Milano 
Italien </p>
<p>Laboratoires Bouchara-Recordati 
Parc Mécatronic<br />
03410 Saint Victor 
Frankrig </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Recordati bv 
Tél/Tel: +32 2 461 01<br />
Lietuva 
Recordati Ireland Ltd. 
Tel: + 353 21 4379България 
Recordati Ireland Ltd. 
Тел.: + 353 21 4379 
Luxembourg/Luxemburg 
Recordati bv 
Tél/Tel: +32 2 461 01 Česká republika 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
Magyarország 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
Danmark 
Recordati Ireland Ltd. 
Tlf.: + 353 21 4379 
Malta 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
Deutschland 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
Nederland 
Recordati bv 
Tel: +32 2 461 01<br />
Eesti 
Recordati Ireland Ltd. 
Tel: + 353 21 4379Norge 
Recordati Ireland Ltd. 
Tlf: + 353 21 4379 
Ελλάδα 
ΒΙΑΝΕΞ Α.Ε. 
Τηλ: + 30 210 8009 
Österreich 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
España 
Almirall, S.A. 
Tel: +34 93 291 30<br />
Polska 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
France 
ZAMBON France 
Tél: + 33 (0)1 58 04 41<br />
Portugal 
Tecnimede Sociedade Técnico-
Medicinal, S.A 
Tel: +351 21 041 41<br />
Hrvatska 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
România 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 </p>
<p>Ireland 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
Slovenija 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
Ísland 
Recordati Ireland Ltd. 
Sími: + 353 21 4379 
Slovenská republika 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
Italia 
Takeda Italia S.p.A. 
Tel: + 39 06 502 
Suomi/Finland 
Recordati Ireland Ltd. 
Puh/Tel: + 353 21 4379 
Κύπρος 
Recordati Ireland Ltd. 
Τηλ: + 353 21 4379 
Sverige 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
Latvija 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 
United Kingdom (Northern Ireland) 
Recordati Ireland Ltd. 
Tel: + 353 21 4379 </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}. </p>
<p>Andre informationskilder 
De kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-9f200c2b1188de65461c6911d6f9550c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for silodyx Package Leaflet for language en"
Description: "ePI document Bundle for silodyx Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-9f200c2b1188de65461c6911d6f9550c"
* entry[0].resource = composition-en-9f200c2b1188de65461c6911d6f9550c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9f200c2b1188de65461c6911d6f9550c"
* entry[=].resource = mp9f200c2b1188de65461c6911d6f9550c
                            
                    
Instance: bundlepackageleaflet-da-9f200c2b1188de65461c6911d6f9550c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for silodyx Package Leaflet for language da"
Description: "ePI document Bundle for silodyx Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-9f200c2b1188de65461c6911d6f9550c"
* entry[0].resource = composition-da-9f200c2b1188de65461c6911d6f9550c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp9f200c2b1188de65461c6911d6f9550c"
* entry[=].resource = mp9f200c2b1188de65461c6911d6f9550c
                            
                    



Instance: mp9f200c2b1188de65461c6911d6f9550c
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Silodyx 4 mg hard capsules"
Description: "Silodyx 4 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/09/607/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Silodyx 4 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 9f200c2b1188de65461c6911d6f9550cListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "silodyx"

* status = #current
* mode = #working

* title = "List of all ePIs associated with silodyx"

* subject = Reference(mp9f200c2b1188de65461c6911d6f9550c)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#silodyx "silodyx"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-9f200c2b1188de65461c6911d6f9550c) // silodyx en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry[+]
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-9f200c2b1188de65461c6911d6f9550c) // silodyx da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-9f200c2b1188de65461c6911d6f9550c
InstanceOf: List
Description: "ePI document List for silodyx Package Leaflets"

* insert 9f200c2b1188de65461c6911d6f9550cListRuleset
    